Skip to main content
Videos

Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Cancer

 

Brian Slomovitz, MD, Mount Sinai Medical Center, Miami, FL, discusses his presentation on the GOG-3026 phase 2 trial of letrozole plus ribociclib for patients with recurrent low-grade serous ovarian cancer at the Society of Gynecologic Oncology's 2023 Annual Meeting on Women's Cancer.


Slomovitz, B. “GOG 3026 A Phase II Trial of Letrozole + Ribociclib in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum: A GOG Foundation Study.” Presented at Society of Gynecologic Oncology Annual Meeting on Women's Cancer; March 25-28, 2022; Miami, FL.